Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer (PRIMO)
Planning Adaptive Treatment by Longitudinal Response Assessment Implementing MR Imaging, Liquid Biopsy and Analysis of Microenvironment During Neoadjuvant Treatment of Rectal Cancer (PRIMO)
Sponsor: Jena University Hospital
A observational or N/A phase clinical study on Adaptive Treatment and Locally Advanced Rectal Carcinoma, this trial is ongoing. The trial is conducted by Jena University Hospital and has accumulated 8 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Oct 2025 [monthly]
Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Apr 2023 — Jul 2024 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Jan 2023 — Apr 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jena University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .